Restricted access

Other

First published online October 12, 2009

Long-Term Miglustat Therapy in Children With Niemann-Pick Disease Type C

Marc C. Patterson, MD, FRACP, Darleen Vecchio, MS, […], Elizabeth Jacklin, RGN, Larry Abel, PhD, Harbajan Chadha-Boreham, MSc, PhD, Cecile Luzy, MSc, Ruben Giorgino, MD, DPhil, and James E. Wraith, MB, ChB, FRCPCH+5View all authors and affiliations

Volume 25, Issue 3

https://doi.org/10.1177/0883073809344222

Abstract
References

Abstract

Niemann-Pick disease type C is a rare, genetic disease associated with impaired intracellular lipid trafficking and progressive neurological symptoms. Miglustat slowed disease progression in a 12-month randomized trial in juveniles and adults with Niemann-Pick disease type C, and in a parallel, noncontrolled study in affected children. Here, the authors report the open-label extension to the pediatric study. Patients aged 4 to 12 years received open-label miglustat (dose adjusted for body surface area) for an initial 12 months, during a further 12-month extension, and a long-term, continued extension phase. Efficacy assessments included horizontal saccadic eye movement, swallowing, and ambulation. Ten children completed 24 months’ treatment. Horizontal saccadic eye movement, ambulation, and swallowing were stabilized at 24 months. Analysis of key parameters of disease progression showed disease stability in 8 of 10 patients (80%). Miglustat stabilized neurological disease progression in pediatric patients with Niemann-Pick disease type C, with comparable safety and tolerability to that observed in adults and juveniles.

Get full access to this article

View all access and purchase options for this article.

References

Meikle PJ, Hopwood JJ, Clague AE, Carey WF Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249-254.

Greer WL, Dobson MJ, Girouard GS, Byers DM, Riddell DC, Neumann PE Mutations in NPC1 highlight a conserved NPC1-specific cysteine-rich domain . Am J Hum Genet. 1999; 65(5):1252-1260.

Vanier MT, Duthel S., Rodriguez-Lafrasse C., Pentchev P., Carstea ED Genetic heterogeneity in Niemann-Pick C disease: a study using somatic cell hybridization and linkage analysis. Am J Hum Genet. 1996;58(1):118-125.

Millat G., Chikh K., Naureckiene S., et al. Niemann-Pick disease type C: spectrum of HE1 mutations and genotype/phenotype correlations in the NPC2 group. Am J Hum Genet. 2001;69(5): 1013-1021.

Naureckiene S., Sleat DE, Lackland H., et al. Identification of HE1 as the second gene of Niemann-Pick C disease. Science. 2000 ;290(5500):2298-2301.

Patterson MC, Vanier MT, Suzuki K., et al. Niemann-Pick disease type C: a lipid trafficking disorder. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001:3611-3633.

Liscum L., Sturley SL. Intracellular trafficking of Niemann-Pick C proteins 1 and 2: obligate components of subcellular lipid transport. Biochim Biophys Acta. 2004;1685(1-3):22-27.

Dawson G. Glycosphingolipid levels in an unusual neurovisceral storage disease characterized by lactosylceramide galactosyl hydrolase deficiency: lactosylceramidosis. J Lipid Res. 1972; 13(2):207-219.

Dawson G., Matalon R., Stein AO Lactosylceramidosis: lactosylceramide galactosyl hydrolase deficiency and accumulation of lactosylceramide in cultured skin fibroblasts. J Pediatr. 1971; 79(3):423-429.

Zervas M., Dobrenis K., Walkley SU Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J Neuropathol Exp Neurol. 2001;60(1):49-64.

Walkley SU, Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta. 2004;1685(1-3):48-62.

Fink JK, Filling-Katz MR, Sokol J., et al. Clinical spectrum of Niemann-Pick disease type C. Neurology. 1989;39(8):1040-1049.

Vanier MT, Millat G. Niemann-Pick disease type C. Clin Genet. 2003 ;64(4):269-281.

Imrie J., Vijayaraghaven S., Whitehouse C., et al. Niemann-Pick disease type C in adults. J Inherit Metab Dis. 2002;25(6):491-500.

Vanier MT, Wenger DA, Comly ME, Rousson R., Brady RO, Pentchev PG Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients . Clin Genet. 1988;33(5): 331-348.

Harzer K., Schlote W., Peiffer J., Benz HU, Anzil AP Neurovisceral lipidosis compatible with Niemann-Pick disease type C: morphological and biochemical studies of a late infantile case and enzyme and lipid assays in a prenatal case of the same family. Acta Neuropathol. 1978;43(1-2):97-104.

Imrie J., Dasgupta S., Besley GT, et al. The natural history of Niemann-Pick disease type C in the UK . J Inherit Metab Dis. 2007;30(1):51-59.

Oyama K., Takahashi T., Shoji Y., et al. Niemann-Pick disease type C: cataplexy and hypocretin in cerebrospinal fluid. Tohoku J Exp Med. 2006;209(3):263-267.

Paciorkowski AR, Westwell M., Ounpuu S., et al. Motion analysis of a child with Niemann-Pick disease type C treated with miglustat. Mov Disord. 2008;23(1):124-128.

Schiffmann R. Niemann-Pick disease type C. From bench to bedside. JAMA. 1996;276(7):561-564.

Platt FM, Neises GR, Dwek RA, Butters TD N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994;269(11):8362-8365.

Zervas M., Somers KL, Thrall MA, Walkley SU Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol. 2001;11(16):1283-1287.

Patterson MC, Vecchio D., Prady H., Abel L., Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007;6(9):765-772.

Patterson MC, Vecchio D., Jacklin E., Wraith JE Miglustat in Niemann-Pick disease Type C (NPC): long-term data from a clinical trial. Presented at: 58th Annual Meeting of the American Society of Human Genetics; 2008; Philadelphia, PA. Abstract #766. http://www.ashg.org/2008meeting/abstracts/fulltext/ Accessed March 1, 2009.

Chien YH, Lee NC, Tsai LK, et al. Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J Inherit Metab Dis. 2007;30(5):826.

Santos ML, Raskin S., Telles DS, et al. Treatment of a child diagnosed with Niemann-Pick disease type C with miglustat: a case report in Brazil. J Inherit Metab Dis. 2008;

Iturriaga C., Pineda M., Fernandez-Valero EM, Vanier MT, Coll MJ. Niemann-Pick C disease in Spain: clinical spectrum and development of a disability scale . J Neurol Sci. 2006; 249(1):1-6.

Solomon D., Winkelman AC, Zee DS, Gray L., Büttner-Ennever J. Niemann-Pick type C disease in two affected sisters: ocular motor recordings and brain-stem neuropathology. Ann N Y Acad Sci. 2005;1039:436-445.

Abel LA, Walterfang M., Fietz M., Bowman EA, Velakoulis D. Saccades in adult Niemann-Pick disease type C reflect frontal, brainstem, and biochemical deficits. Neurology. 2009;72(12): 1083-1086.

You currently have no access to this content. Visit the access options page to authenticate.